ABBV AbbVie Inc.

72.67
-1.16  -2%
Previous Close 73.83
Open 71.63
Price To Book -13.14
Market Cap 107,309,812,957
Shares 1,476,672,808
Volume 12,290,507
Short Ratio
Av. Daily Volume 13,137,926
Stock charts supplied by TradingView

NewsSee all news

  1. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., March 23, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  2. AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

    NORTH CHICAGO, Ill., March 23, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with

  3. AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction

    NORTH CHICAGO, Ill. and DUBLIN, March 17, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced

  4. AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia

    NORTH CHICAGO, Ill., March 12, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in

  5. AbbVie Announces New Formulary Listings for SKYRIZI® in the Treatment of Moderate to Severe Plaque Psoriasis

    SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe psoriasis.1   In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16 weeks and maintained

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Depatuxizumab mafodotin ABT-414
Glioblastoma (rGBM)
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Alzheimer's disease
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due in 2021.
Venetoclax - CANOVA
Relapsed or refractory multiple myeloma
FDA approval announced April 23, 2019.
Risankizumab
Psoriasis
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Phase 3 trial to commenced 2017.
ABT-494
Psoriatic Arthritis
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 3 trial met primary and secondary endpoints - October 31, 2019.
Upadacitinib
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
NDA filing announced August 5, 2019. PDUFA date 2Q 2020. Exact date not provided. Estimate June 4, 2020 based on 10-month timeline.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
FDA Approval announced August 16, 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Rova-T (MERU)
First-line Small Cell Lung Cancer
FDA approval announced January 28, 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
Phase 3 primary endpoint not met (PFS/OS).
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
sNDA filing announced June 4, 2019.
Venetoclax and obinutuzumab
Chronic lymphocytic leukemia
Phase 3 presentation at ESMO 28 September 2019.
Veliparib
Ovarian cancer
Phase 3 data presented at EADV October 10, 2019.
Risankizumab ( LIMMITLESS )
Psoriasis
sNDA filing announced November 8, 2019.
IMBRUVICA (ibrutinib) and rituximab
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Phase 3 trial met primary endpoint - January 14, 2020.
Risankizumab vs secukinumab
Plaque psoriasis
Phase 3 trial did not meet primary endpoint - February 28, 2020.
Venetoclax - Viale-C
Treatment-naïve Acute Myeloid Leukemia
Phase 3 primary endpoint met - February 5, 2020. sNDA filing due 2Q 2020.
Upadacitinib - SELECT-NEXT
Psoriatic arthritis
Phase 3 data due 2020.
Risankizumab MOTIVATE
Crohn’s Disease
Phase 3 data due 2020.
Risankizumab KEEPSAKE2
Psoriatic Arthritis
Phase 3 data due 2020.
Risankizumab vs secukinumab
Psoriasis
Phase 3 data due 2020.
Upadacitinib
Atopic dermatitis
Phase 3 trial met dual primary endpoints of overall survival and composite complete remission rate - March 23, 2020.
Venclexta (VIALE-A)
Acute Myeloid Leukemia (AML)
Phase 2 data due 2020.
Imbruvica + Venclexta (CAPTIVATE)
Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Phase 3 data due 2020.
Ibrutinib in combination with prednisone
Chronic Graft Versus Host Disease
Phase 3 data due 2021.
ABBV-951
Parkinson's disease

Latest News

  1. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., March 23, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  2. AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

    NORTH CHICAGO, Ill., March 23, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with

  3. AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction

    NORTH CHICAGO, Ill. and DUBLIN, March 17, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced

  4. AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia

    NORTH CHICAGO, Ill., March 12, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in

  5. AbbVie Announces New Formulary Listings for SKYRIZI® in the Treatment of Moderate to Severe Plaque Psoriasis

    SKYRIZI® is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe psoriasis.1   In clinical studies, SKYRIZI® significantly improved levels of skin clearance after just 16 weeks and maintained

  6. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  7. AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19

    NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) today confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of

  8. European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

    NORTH CHICAGO, Ill., March 6, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has approved a change to the marketing authorization

  9. AbbVie and Allergan Receive Final European Approval to Close Pending Transaction

    NORTH CHICAGO, Ill. and DUBLIN, March 3, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced

  10. AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)

    NORTH CHICAGO, Ill., Feb. 28, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with

  11. VENCLEXTA® with Rituximab, a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL), now reimbursed in British Columbia

    British Columbia is the second province to reimburse the combination treatment. VENCLEXTA® + rituximab is a regimen that includes a targeted oral agent that should be continued for two years after initial five weeks

  12. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., Feb. 24, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  13. AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 20, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.18 per share.  The cash dividend is payable May 15, 2020 to

  14. AbbVie to Present at the Cowen 40th Annual Health Care Conference

    NORTH CHICAGO, Ill., Feb. 19, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will participate in the Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020. 

  15. AbbVie's SKYRIZI™ Now Listed on the Nova Scotia Formulary for the Treatment of Moderate to Severe Plaque Psoriasis

    SKYRIZI™ is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe psoriasis.1 In clinical studies, SKYRIZI™ significantly improved levels of skin clearance after just 16 weeks and maintained

  16. AbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    NORTH CHICAGO, Ill., Feb. 11, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will participate in the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February

  17. AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results

    NORTH CHICAGO, Ill., Feb. 7, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2019. "Our strong performance this quarter completes another

  18. AbbVie's SKYRIZI™ Now Publicly Reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the Treatment of Moderate to Severe Plaque Psoriasis

    SKYRIZI™ is an interleukin-23 (IL-23) inhibitor used for the treatment of moderate to severe psoriasis.1 In clinical studies, SKYRIZI™ significantly improved levels of skin clearance after just 16 weeks and maintained

  19. RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis

    NORTH CHICAGO, Ill., Feb. 5, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1 clinical trial. In this

  20. AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis

    NORTH CHICAGO, Ill., Jan. 31, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the

  21. AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia

    NORTH CHICAGO, Ill., Jan. 31, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European

  22. Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer's Disease Patients

    - Phase 1b study of AL003 will enroll approximately 12 Alzheimer's disease patients to assess safety, pharmacokinetics and pharmacodynamics, and monitor target specific biomarkers SOUTH SAN FRANCISCO, Calif., Jan.

  23. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., Jan. 27, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  24. AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

    NORTH CHICAGO, Ill. and DUBLIN, Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE:AGN), a leading global pharmaceutical company, today announced that

  25. New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks

    NORTH CHICAGO, Ill., Jan. 14, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI™ met both primary and all ranked secondary endpoints, including

  26. AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary

    MAVIRET® is an 8-week, pan-genotypic treatment for adults and adolescent patients 12 to 18 years of age with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1 MAVIRET is approved

  27. AbbVie to Host Fourth-Quarter and Full-Year 2019 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 13, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2019 financial results on Friday, February 7, 2020

  28. AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition

    NORTH CHICAGO, Ill., Jan. 8, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and

  29. AbbVie Receives Health Canada Approval of RINVOQ® (upadacitinib), an Oral Medication for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

    Approval supported by efficacy and safety data from the pivotal Phase 3 SELECT rheumatoid arthritis (RA) program, one of the largest registrational Phase 3 programs in RA with approximately 4,400 patients evaluated

  30. AbbVie to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NORTH CHICAGO, Ill., Jan. 3, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15,

  31. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., Dec. 20, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  32. AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

    Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA)i, Quebec is the first province to reimburse the combination treatment. VENCLEXTA® + rituximab is a regimen that

  33. AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

    NORTH CHICAGO, Ill., Dec. 18, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved RINVOQ™ (upadacitinib) for the

  34. Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

    SEATTLE, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT) today announced a multi-year, global collaboration agreement with AbbVie (NYSE:ABBV) to utilize Adaptive's next-generation

  35. AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics

    NORTH CHICAGO, Ill. and LA JOLLA, Calif., Dec. 9, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research

  36. New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    NORTH CHICAGO, Ill., Dec. 8, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical

  37. More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen

    NORTH CHICAGO, Ill., Dec. 7, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA®

  38. IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

    NORTH CHICAGO, Ill., Dec. 7, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial,1 evaluating

  39. Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)

    NORTH CHICAGO, Ill., Dec. 7, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study –

  40. Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

    - Today's AL002 presentation showcases the first data in humans with a TREM2 antibody - AL002 was generally safe and well-tolerated in healthy volunteers - Reduced CSF sTREM2 level demonstrates target engagement -

  41. AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

    Psoriasis is a chronic condition affecting 125 million people worldwide and many patients despite treatment still do not reach their goals or lose treatment response over time. 1-3 SKYRIZI™ is a novel, humanized

  42. Mission and AbbVie's Collaboration in Alzheimer's and Parkinson's Diseases Reaches Milestone

    Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie ("AbbVie")(NYSE:ABBV), a global, research-driven biopharmaceutical

  43. AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting

    NORTH CHICAGO, Ill., Nov. 21, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that more than 40 abstracts, including 18 oral presentations, will be presented

  44. Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon's BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

    Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration includes up to six

  45. Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

    Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology.  AbbVie receives exclusive options to license a number of Dragonfly's natural

  46. AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill., Nov. 18, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and,

  47. AbbVie Prices $30 Billion of Senior Unsecured Notes

    NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today that it has priced its previously announced private offering (the "Offering") of senior unsecured

  48. New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting

    NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2/3 SELECT-AXIS 1 trial in which twice as many adult

  49. AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia

    NORTH CHICAGO, Ill., Nov. 8, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and

  50. AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes

    NORTH CHICAGO, Ill., Nov. 7, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the

  51. AbbVie Announces Launch of Private Offering of Senior Unsecured Notes

    NORTH CHICAGO, Ill., Nov. 6, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today that it has launched a private offering (the "Offering") of senior unsecured notes (the

  52. AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting

    NORTH CHICAGO, Ill., Nov. 4, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of RINVOQ™ (upadacitinib), HUMIRA®

  53. AbbVie Reports Third-Quarter 2019 Financial Results

    NORTH CHICAGO, Ill., Nov. 1, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2019. "Strong performance from our Immunology and Hematologic Oncology

  54. RINVOQ™ (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis

    NORTH CHICAGO, Ill., Oct. 31, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced positive top-line data from the SELECT-PsA 2 Phase 3 study. In this study, both

  55. AbbVie to Present at the Wolfe Research Inaugural Healthcare Conference

    NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will participate in the Wolfe Research Inaugural Healthcare Conference on Wednesday, November 6. 

  56. AbbVie Announces Collaboration with Cystic Fibrosis Foundation

    NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and the Cystic Fibrosis Foundation, announced today a strategic collaboration in which AbbVie will

  57. AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress

    NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™

  58. AbbVie to Host Third-Quarter 2019 Earnings Conference Call

    NORTH CHICAGO, Ill., Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market

  59. Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction

    DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

  60. AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

    NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE:AGN) have each received a Request

  61. AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

    NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval

  62. VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada

    MONTREAL, Sept. 25, 2019 /CNW/ - AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced today that Alberta, Manitoba, British Columbia and Saskatchewan are listing VENCLEXTA®

  63. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  64. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  65. AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®

    NORTH CHICAGO, Ill., Sept. 23, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present results from two late-breaking

  66. Thinking about buying stock in AbbVie, Aurora Cannabis, Catalyst Pharmaceuticals, Fibrocell Science, or MER Telemanagement Solutions?

    NEW YORK, Sept. 13, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, ACB, CPRX, FCSC, and MTSL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  67. Advances in Biotechnology May Offer Cancer Patients Renewed Hope

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- The biotechnology market is currently one of the largest industries in the world. Biotechnology is defined as technology that is used to modify or upgrade the biological system,

  68. AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Sept. 6, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) declared a quarterly cash dividend of $1.07 per share.  The cash dividend is payable November 15, 2019 to stockholders

  69. AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program

    NORTH CHICAGO, Ill., Aug. 29, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy

  70. AbbVie to Present at the Morgan Stanley Healthcare Conference

    NORTH CHICAGO, Ill., Aug. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday,